Evidences that zidovudine (AZT) could not be directly responsible for iron overload in AZT-treated patients: An in vitro study

Clinica Chimica Acta

Volumn 300, Issue 1-2, 2000, Pages 119-130

  D'Alessandro, Anna M ^a   Rinaldi, Andrea C ^a   D'Andrea, Gabriele ^a   Brisdelli, Fabrizia ^a   Di Ciccio, Luciano ^a   Di Giulio, Antonio ^a   Oratore, Arduino ^a   Bozzi, Argante ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

AZT; Calcein; Iron chelation; Iron overload; K562 cells; Transferrin; Transferrin receptor; Zidovudine

Indexed keywords

CALCEIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; ZIDOVUDINE;

ANEMIA; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; PRIORITY JOURNAL;

ANTI-HIV AGENTS; HUMANS; IRON; IRON OVERLOAD; K562 CELLS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0033839223     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(00)00314-4     Document Type: Article

References (27)

1. Boelaert J.R., Weinberg G.A., Weinberg E.D. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis. 5:1996;36-46.
2. Goldin R.D., Wilkins M., Dourakis S., Parkin J., Lindley R. Iron overload in multiply transfused patients who are HIV seropositive. J Clin Pathol. 46:1993;1036-1038.
3. Kreuzer K.A., Rockstroh J.K. Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol. 75:1997;179-187.
4. Richman D.D., Fischl M.A., Grieco M.H., et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New Engl J Med. 317:1987;192-197.
5. Furman P.A., Fyfe J.A., St Clair M.H., et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA. 83:1986;8333-8337.
6. Weidner D.A., Sommadossi J.-P. 3′-Azido-3′-deoxythymidine inhibits globin gene transcription in butyric acid-induced K562 human leukemia cells. Mol Pharmacol. 38:1990;797-804.
7. Weidner D.A., Bridges E.G., Cretton E.M., Sommadossi J.-P. Comparative effects of 3′-azido-3′-deoxythymidine and its metabolite 3′-amino-3′-deoxythymidine on hemoglobin synthesis in K562 human leukemia cells. Mol Pharmacol. 41:1992;252-258.
8. Cretton E.M., Xie M.Y., Bevan R.J., Goudgaon N.M., Schinazi R.F., Sommadossi J.-P. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol. 39:1991;258-266.
9. Pollack S., Weaver J. Azidothymidine (AZT)-induced siderosis. Am J Hematol. 43:1993;230-233.
10. Lutton J.D., Mathew A., Levere R.D., Abraham N.G. Role of heme metabolism in AZT-induced bone marrow toxicity. Am J Hematol. 35:1990;1-5.
11. Lindley R., Parkin J., Dourakis S., Goldin R. Iron deposition in liver in zidovudine-related transfusion-dependent anaemia. Lancet. 11:1989;681.
12. D'Alessandro A.M., D'Andrea G., Di Ciccio L., et al. 3′-Azido-3′-deoxythymidine reduces the rate of transferrin receptor endocytosis in K562 cells. Biochim Biophys Acta. 1450:1999;232-241.
13. Pippard M.J., Johnson D.K., Finch C.A. Hepatocyte iron kinetics in the rat explored with an iron chelator. Br J Haematol. 52:1982;211-224.
14. Breuer W., Epsztejn S., Cabantchik Z.I. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem. 270:1995;24209-24215.
15. Di Giulio A., D'Andrea G., Saletti M.A., Impagnatiello A., D'Alessandro A.M., Oratore A. The binding of human serum transferrin to its specific receptor reconstituted into liposomes. Cell Sign. 6:1994;83-90.
16. Carver F.J., Frieden E. Factors affecting the adenosine triphosphate induced release of iron from transferrin. Biochemistry. 17:1978;167-172.
17. Cabantchik Z.I., Glickstein H., Milgram P., Breuer W. A fluorescence assay or assessing chelation of intrecellular iron in a membrane model system and in mammalian cells. Anal Biochem. 233:1996;221-227.
18. Harford J.B. Cellular iron homeostasis: a paradigm for mechanisms of post-transcriptional control of gene expression. Prog Liver Dis. 12:1994;47-62.
19. Beard J.L., Dawson H., PiZero D.J. Iron metabolism: a comprehensive review. Nutrit Rev. 54:1996;295-317.
20. Haile D.J., Rouault T.A., Tang C.K., Chin J., Harford J.B., Klausner R.D. Reciprocal control of RNA-binding and aconitase activity in the regulation of the iron-responsive element binding protein: role of the iron-sulfur cluster. Proc Natl Acad Sci USA. 89:1992;7536-7540.
21. r iron isolated from guinea pig reticulocytes as AMP-Fe and ATP-Fe complexes. Biochem J. 261:1989;787-792.
22. Weaver J., Zhan H., Pollack S. Mitochondria have Fe(III) receptors. Biochem J. 265:1990;415-419.
23. Lucarelli M., Palitti F., Carotti D., et al. AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation. FEBS Lett. 396:1996;323-326.
24. Tornevik Y., Ullman B., Balzarini J Wahren B., Erikson S. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azido-3′-deoxythymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azido-3′-deoxythymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lynphoblastoid cells. Biochem Pharmacol. 49:1995;829-837.
25. Di Vito M., Bozzi A., Ferretti A., et al. Intracellular metabolism of 3′-azido-3′-deoxythymidine (AZT): a nuclear magnetic resonance study on T-lymphoblastoid cell lines with different resistance to AZT. Biochem Pharmacol. 54:1997;979-990.
26. Balzarini J., Pauwels R., Baba M., et al. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol. 37:1988;897-903.
27. Hershko C., Link G., Cabantchik Z.I. Pathophysiology of iron overload. Ann New York Acad Sci. 850:1998;191-201.